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Introduction
In the research and development of new drug candidates it has become standard practice to evaluate metabolism of these candidates using human in vitro hepatic models (Plant, 2004; Pelkonen and Raunio, 2005; Dalvie et al., 2009; Wang et al., 2010; Ballard et al., 2014) . The aims of this endeavor are to provide an understanding of the initial metabolic pathways as a first look at the possible enzymes involved in drug clearance and to also provide as comprehensive a picture of the metabolic profile as possible as a forecast of the metabolite profile that will be observed in humans in vivo. To the latter aim, gathering corresponding metabolite profile data in the same in vitro systems derived from common laboratory animal species can add strength to the prediction of the human in vivo metabolic profile if there is agreement between the animal in vitro systems and the metabolite profiles observed in these species in vivo.
In addition to understanding drug clearance, cross-species comparisons of drug metabolite profiles are also important from a drug safety standpoint. Laboratory animal species, such as rat, dog, and monkey, among others, are commonly used to test the safety of new drug candidates prior to administration to humans. Risk assessments are derived from the observations of toxicity and the toxicokinetics of the parent drug; however, it is possible that toxicity can be caused not by the parent drug, but by a drug metabolite(s). Thus, it is important that laboratory animal species are exposed to the same metabolites to which humans will be exposed. This is highlighted in the Metabolites in Safety Testing guidances that have been issued by government and international drug regulatory authorities over the past decade (FDA and U.S. Department of Health and Human, 2010) .
In vitro hepatic derived systems most commonly used to generate cross-species drug metabolite profiles include subcellular fractions from liver (microsomes, cytosol, S-9 fraction) and suspensions of primary cryopreserved hepatocytes (Kerns and Di, 2008) . While these systems are mostly successful in generating realistic drug metabolite profiles (Dalvie et al., 2009 ), they suffer from activity being relatively short-lived (timeframe of minutes to a few hours) (Foti and Fisher, 2004; Gomez-Lechon et al., 2008; Smith et al., 2012) , and if a new drug candidate is slowly but extensively metabolized, the in vitro metabolite profile generated may fall short of being an adequate reflection of the in vivo profile. This D M D # 6 6 6 8 8 5 problem is not overcome by standard hepatocyte culture systems because of down-regulation of drug metabolizing enzymes in these systems (Gomez-Lechon et al., 2008) . Recent advances in tissue engineering have led to the development of in vitro models that more closely mimic the in vivo system and express drug metabolism activity over a period of days, including liverchip (Dash et al., 2009 ) and micropatterned co-culture (MPCC) systems (Khetani and Bhatia, 2008; Wang et al., 2010; Chan et al., 2013) . In our laboratory we have described the use of the human hepatocyte relay method as well as the MPCC system to generate human metabolite profiles that included relevant secondary metabolites that are otherwise challenging to generate using simple in vitro systems (Wang et al., 2010; Ballard et al., 2014 ). In the study described herein we have extended this effort to include an examination of the MPCC system derived from laboratory animal species with the objective of determining whether cross-species comparisons of metabolite profiles can be generated. We selected test compounds known to have crossspecies differences in metabolite profiles due to known differences in enzyme activity (e.g. CYP2C family, UGT1A4, aldehyde oxidase and N-acetyltransferase). Thus, such a system can be effectively leveraged in identifying those instances where one or more laboratory animal species may not yield an important human metabolite.
Materials and Methods
Materials. Procainamide, tolbutamide, trifluoperazine and trovafloxacin were purchased from Sigma Aldrich (St. Louis, MO). Sunitinib was purchased from AK Scientific (Union City, CA). Zoniporide and carbazeran were obtained from Pfizer Global Material Management (Groton, CT). Micro-patterned co- The supernatants were dried in a Genevac™ evaporative centrifuge and the resulting residues were reconstituted in 100 µL of 95% water / 5% acetonitrile, centrifuged (1280 x g, 5 min) and analyzed by LCMS.
UHPLC-Tandem Mass Spectrometry Analysis. Reconstituted samples were analyzed by UHPLC-UV-MS operated in positive or negative ion mode using an Orbitrap Elite mass spectrometer. For UHPLC-UV-MS analysis, the capillary temperature was set at 275 °C, the source potential was 3500 V and the source heater was set at 425 °C. The mass spectrometer was operated in a data-dependent scanning mode to MS 3 with dynamic exclusion enabled (repeat count: 1; repeat duration: 5.0 s; list size: 500; exclusion duration: 1.5 s). The normalized collision energy for the data-dependent scans was 35%. Other potentials were adjusted as necessary to get optimal ionization and fragmentation of the parent compound. UV absorption spectra were obtained by an in-line Accela photodiode array detector. Although each compound required a slightly different gradient system, in general a Kinetex C18 100 Å column (Phenomenex, Torrance, CA) was used (2.1 x 150 mm, 1.7 µm) with a flow rate of 0.4 mL/min at 45 °C.
Mobile phase A was comprised of 0.1% formic acid and mobile phase B was comprised of acetonitrile.
The gradient system used was: initially, 5% B held for 0.8 min followed by a linear gradient to 50% B from 
Results and Discussion
The early detection of human specific metabolites is of great importance in the research and development of drug candidates. Just as important is the proper choice of preclinical species used to represent the expected human in vivo metabolic drug profile. Incorrect choice of preclinical species, which would provide incorrect drug depletion and metabolic profiles, could negatively affect the success of a drug candidate. A recent example of this was described by Taub et. al. wherein mice predominately generated a toxic metabolite that was not formed in humans (Taub et al., 2015) . Additionally, metabolites may have inherent biological activity or toxicity and tools capable of better predicting these events are sorely needed. To this end, we investigated micropatterned co-cultured (MPCC) hepatocytes of human and preclinical species in their ability to recapitulate known in vivo profiles of selected test compounds that possess dissimilar metabolic profiles across species. This is not to say that we are only investigating human unique metabolites. It is quite the opposite in that we are investigating species-unique metabolites that may impact preclinical and clinical PKPD, safety and toxicology, including human unique metabolites.
The successful establishment of preclinical species comparison with MPCC hepatocytes can be a useful and efficient tool to evaluate metabolic species difference, and also aid preclinical species selection providing higher confidence in a successful transition to human clinical trials.
To investigate the robustness of the MPCC multi-species hepatocyte system we chose several test compounds with primary major routes of metabolism through CYP2C9 (tolbutamide), aldehyde oxidase (carbazeran and zoniporide), UGT1A4 (trifluoperazine) and N-acetyltransferase (procainamide) ( Figure 1 and , 1997) . Monkey metabolism data was not available for trovafloxacin, however the major metabolite was produced as would be expected based on known conservation of UGT1A1 activity across species (King et al., 1996; Berry et al., 2014) . It was also noted with these initial studies that the replicate human donors all performed satisfactorily with negligible differences between donors. With satisfactory evidence that the MPCC hepatocyte system was recapitulating in vivo data with conserved enzymes across species, we set out to probe the system with our test compounds.
Carbazeran (3) is a phosphodiesterase inhibitor that is primarily metabolized by aldehyde oxidase (AO) to 4-oxo-carbazeran (3a) in human, while this specific oxidation is absent in dogs (Kaye et al., 1984) . Zoniporide (4) was being developed to reduce perioperative myocardial ischemic injury in high-risk surgery patients by inhibition of the sodium/hydrogen exchanger. Zoniporide is another drug that is now known to be extensively metabolized by AO forming 2-oxo-zoniporide (4a) in both humans and rats but not in dogs and its cross-species metabolism has also been reported (Dalvie et al., 2010) . Owing to the low clearance rate of zoniporide (4), the 7 day MPCC hepatocyte system time point displayed formation of the expected AO product in human, monkey (unknown but not unexpected) and rat ( Figure 3 ). A monkey unique metabolite (A) was also noted which appeared to be further oxidation of 4a to introduce a hydroxyl on the phenyl ring. Dog MPCC hepatocytes also appeared to produce a small amount of the AO product (4a) yet dogs are devoid of AO activity (Terao et al., 2006; Kurosaki et al., 2013) . Comparison of the dog MPCC metabolite with a synthetic standard of the AO metabolite (4a) definitively confirmed its structure as 2-oxo-zoniporide (4a). We found that this metabolite was also formed in suspended dog hepatocytes (also small), perhaps being overlooked in previous studies. We followed up these results in suspended human and dog hepatocytes to determine the enzymatic origin of the metabolite as its production by AO did not appear feasible ( Figure 4AB ). The zoniporide AO metabolite (4a) was inhibited
by hydralazine (HDZ) in human hepatocytes confirming AO as the human enzyme responsible; however, 1-aminobenzotriazole (ABT) was required to inhibit metabolite formation in dog hepatocytes providing evidence for a complementary CYP-mediated pathway to form 2-oxo-zoniporide (4a) in dog. Qualitatively, the multi-species MPCC hepatocyte system recapitulated the in vivo major metabolite profile producing 2-oxo-zoniporide (4a) in human, monkey and rat; however, dog hepatocytes appear to have a previously unknown compensatory pathway to also form 2-oxo-zoniporide.
Tolbutamide (5) is a low clearance potassium channel blocker that is used to treat type 2 diabetes. The major excretory metabolite in human and rat is 4-hydroxytolbutamide (5a) catalyzed mainly by CYP2C9, with some production of 4-carboxytolbutamide (5b) as well (Thomas and Ikeda, 1966) . In our study with multi-species MPCC hepatocytes, human donors were able to produce 4-hydroxy-tolbutamide (5a) as the major metabolite with smaller amounts of carboxytolbutamide (5b) formed. Monkey and rat were able to produce 4-hydroxytolbutamide (5a) while dog failed to produce it at all ( Figure 5 ). It was anticipated that dog would not form the 4-hydroxy metabolite (5a) due to the polymorphic and semi-homologous nature of the dog CYP2C family (Blaisdell et al., 1998; Graham et al., 2003) . As an example of non-human specific metabolites, an amide hydrolysis product (5c) is also known to be formed in dog and rat but not in human.
Using an authentic standard for comparison, the hydrolysis product was not detected in human but was formed in dog and rat consistent with known literature (Supplemental Figure 3 ) (Gee et al., 1984; Back and Orme, 1989) . The multi-species MPCC hepatocyte system accurately recapitulated the human and known preclinical species' metabolism profiles of tolbutamide providing evidence for the usefulness of such a system in early-stage research and development efforts.
Procainamide (6) is a low clearance antiarrhythmic used to treat abnormal heart rhythms. Nacetylprocainamide (6a) is the major human metabolite and it also possesses similar potency as the parent drug (Minchin et al., 1978) . N-Acetyltransferase (NAT) catalyzes the acetylation of many aniline containing drugs, including procainamide, in humans and other species; however, the NAT gene is completely absent in dogs (Trepanier et al., 1997) . After a 7 day incubation in the multi-species MPCC hepatocyte system, human, monkey and rat produced N-acetylprocainamide (6a) as the major
metabolite; however, dog also generated a small amount of the acetylated product ( Figure 6 ). As the production of this metabolite in dog by NAT was completely impossible, we followed up these results in suspended human and dog hepatocytes (data not shown). In suspended hepatocytes, dog did not produce the metabolite while human did suggesting the MPCC system is producing a false positive for NAT activity. The MPCC system uses human fibroblasts for dog matrix co-culture while all other species are co-cultured with mouse fibroblasts. We hypothesized that the human fibroblasts were providing NAT activity to the dog MPCC system generating a false-positive metabolite. Upon incubations of procainamide (6) in human fibroblast cells, the N-acetylprocainamide metabolite (6a) was produced in qualitatively similar amounts after a 7 day incubation period as compared to the dog MPCC hepatocytes, confirming our hypothesis (data not shown). The other compounds in our study were not tested in fibroblasts and we cannot exclude that fibroblasts may form some of the minor metabolites; however, fibroblasts are not known to possess significant phase 1 (i.e. CYP, AO) or phase II (i.e. NAT, UGT) enzymatic activity (Cui et al., 2000; Moriwaki et al., 2001; Du et al., 2014) . Overall, the MPCC hepatocyte system recapitulated in vivo metabolism data when controlled for the stromal cell component which should be monitored in dog specifically.
Trifluoperazine (7) is a moderate clearance anti-psychotic drug used in the treatment of schizophrenia.
Trifluoperazine is an old drug and does not have published in vivo human data (it may never have been run) but its major metabolite from human in vitro systems was an N-glucuronide (7a) and it was later shown to be solely mediated by human UGT1A4 (Uchaipichat et al., 2006) . Both in vitro and in vivo studies in rats failed to produce the same N-glucuronide (7a) product although rapid N-demethylation (7b) was observed (Gaertner et al., 1974; Breyer and Schmalzing, 1977) . The multi-species MPCC hepatocyte system formed the N-glucuronide (7a) in both human and monkey while dog and rat did not produce the metabolite (Figure 7 ). There is no in vivo data to support or refute formation in monkey or dog but the system's ability to recapitulate human and rat profiles was exceptional. In vitro studies with trifluoperazine and other substrates have highlighted human and preclinical species UGT1A4 differences (Kaku et al., 2004; Xiao et al., 2014; Troberg et al., 2015) . Additionally, N-desmethyl-trifluoperazine (7b) was formed
across all species as an example of a conserved cross-species metabolite and provides evidence that the system is functioning appropriately.
Conclusions
The MPCC hepatocyte system successfully recapitulated the human and preclinical species' metabolites catalyzed by both phase I and phase II enzymes with compounds representing diverse clearance rates and metabolic liabilities. While pooled human liver microsomes, liver S-9 fraction and hepatocytes have been shown to be effective at predicting primary human metabolites in vivo (Dalvie et al., 2009 ), human MPCC hepatocytes have shown success at predicting both primary and secondary major human excretory and circulating metabolites, especially for low turn-over compounds (Wang et al., 2010) . With the development of a multi-species MPCC hepatocyte system encompassing human, monkey, dog and rat co-cultured hepatocytes on one plate, preclinical in vitro metabolism studies could be conducted simultaneously to better predict both human and preclinical major circulating and excretory metabolites.
Evaluation of seven diverse test compounds yielded good correlation between in vivo metabolite profiles and in vitro MPCC hepatocyte profiles across human and preclinical species ( Table 2 ). The qualitative cross-species MPCC metabolite profiles of the investigational compounds also generally agreement with reported clearance data displaying parent depletion in close agreement with in vivo half-life data across species. Dog MPCC hepatocytes did produce some discrepancies but were able to be mitigated and contextualized by comparison of incubations in the control fibroblasts and with targeted inhibition studies.
Although our test compounds provided good in vitro-in vivo correlation, there is still a need to better investigate the system with compounds displaying sequential and multiple routes of metabolism in preclinical species. Overall, the multi-species MPCC hepatocyte system is a predictive preclinical tool to investigate the qualitative cross-species in vitro metabolite profiles of investigational new drugs in preparation for in vivo preclinical and clinical toxicology and efficacy trials. (Xiao et al., 2014) This article has not been copyedited and formatted. The final version may differ from this version. 
